StockData
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.73+0.01 (+0.58%)

Close on Nov 18, 2026Market cap $36.39MP/E –Yield –

Grace Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Grace Therapeutics's gross profit for the twelve months ending Mar 31, 2022 was $100.00M, up 83233.3% year over year. For fiscal 2022 it was $100.00M, up 83233.3% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2022Mar 31, 2022$100.00M+83233.3%
FY2021Mar 31, 2021$120.00K–

Quarterly gross profit

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2022CQ1 2022Mar 31, 2022$100.00M–
Q3 FY2022CQ4 2021Dec 31, 2021$0–
Q4 FY2021CQ1 2021Mar 31, 2021$75.00K–
Q3 FY2021CQ4 2020Dec 31, 2020$45.00K–

More Grace Therapeutics figures

See a number that looks wrong?